These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26944462)

  • 61. Estrogen therapy in older patients with recurrent urinary tract infections: a review.
    Rozenberg S; Pastijn A; Gevers R; Murillo D
    Int J Fertil Womens Med; 2004; 49(2):71-4. PubMed ID: 15188831
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of hormone replacement therapy on sexuality in postmenopausal women in a mideast country.
    Omu AE; al-Qattan N
    J Obstet Gynaecol Res; 1997 Apr; 23(2):157-64. PubMed ID: 9158303
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
    Nappi RE; Palacios S
    Climacteric; 2014 Feb; 17(1):3-9. PubMed ID: 24423885
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response.
    Lara LA; Useche B; Ferriani RA; Reis RM; de Sá MF; de Freitas MM; Rosa e Silva JC; Rosa e Silva AC
    J Sex Med; 2009 Jan; 6(1):30-9. PubMed ID: 19170834
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacotherapy for women's sexual dysfunction.
    Basson R
    Expert Opin Pharmacother; 2009 Jul; 10(10):1631-48. PubMed ID: 19527189
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?
    Schiavi MC; Sciuga V; Giannini A; Vena F; D'oria O; Prata G; Di Tucci C; Savone D; Aleksa N; Capone C; Di Mascio D; Meggiorini ML; Monti M; Zullo MA; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2018 Aug; 34(8):666-669. PubMed ID: 29463148
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women.
    Raghunandan C; Agrawal S; Dubey P; Choudhury M; Jain A
    J Sex Med; 2010 Mar; 7(3):1284-90. PubMed ID: 20102444
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sequential treatment in vulvovaginal atrophy.
    Palacios S
    Climacteric; 2023 Aug; 26(4):292-295. PubMed ID: 37105219
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Estrogen and its effect on vaginal atrophy in post-menopausal women.
    Kelley C
    Urol Nurs; 2007 Feb; 27(1):40-5. PubMed ID: 17390926
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
    Simon J; Portman D; Mabey RG;
    Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of ospemifene or lubricants on clinical signs of VVA.
    Constantine G; Graham S; Koltun WD; Kingsberg SA
    J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Testosterone therapy for sexual dysfunction in postmenopausal women.
    Hubayter Z; Simon JA
    Climacteric; 2008 Jun; 11(3):181-91. PubMed ID: 18568783
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Urogenital aging: solutions in clinical practice.
    Notelovitz M
    Int J Gynaecol Obstet; 1997 Oct; 59 Suppl 1():S35-9. PubMed ID: 9386214
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy.
    Nappi RE; Murina F; Perrone G; Villa P; Biglia N
    Minerva Ginecol; 2017 Aug; 69(4):370-380. PubMed ID: 28398023
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.
    Sharifi M; Lewiecki EM
    Expert Rev Clin Pharmacol; 2014 May; 7(3):281-91. PubMed ID: 24580081
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive.
    Serati M; Bogani G; Di Dedda MC; Braghiroli A; Uccella S; Cromi A; Ghezzi F
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():48-50. PubMed ID: 26070127
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Emerging therapies for postmenopausal vaginal atrophy.
    Pickar JH
    Maturitas; 2013 May; 75(1):3-6. PubMed ID: 23434231
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes.
    Smith CL; Santen RJ; Komm B; Mirkin S
    Breast Cancer Res; 2014 Jun; 16(3):212. PubMed ID: 25928299
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Female Sexual Function at Midlife and Beyond.
    Thomas HN; Neal-Perry GS; Hess R
    Obstet Gynecol Clin North Am; 2018 Dec; 45(4):709-722. PubMed ID: 30401552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.